Explore the vast range of titles available.

Introduction Clozapine is an atypical antipsychotic widely used in treatment-resistant schizophrenia. While it is commonly associated with orthostatic hypotension, clozapine-induced hypertension is a rare but reported adverse effect with unclear mechanisms. Patient Information We report the case of a 26-year-old with treatment-resistant schizophrenia, without significant medical history, hospitalized after a suicide attempt. Clinical Findings Shortly after clozapine initiation with gradual dose titration, the patient developed sustained hypertension (up to 170/90mmHg) without any other identifiable cause. Cardiac evaluations, laboratory tests, and imaging studies excluded alternative etiologies. Clozapine therapy was continued due to therapeutic resistance, with the addition of antihypertensive medications (nicardipine and rilmenidine) and close blood pressure monitoring. Conclusion Although rare, clozapine-induced hypertension requires increased clinical awareness, especially during the early weeks of treatment. Systematic blood pressure monitoring is essential to timely identify and manage this cardiovascular risk.

Introduction: schizophrenic relapse constitutes a formidable challenge in the realm of psychiatric care, often precipitating a cascade of deteriorating symptoms and functional impairment. Addressing this issue necessitates a comprehensive understanding of the factors that contribute to relapse occurrence. Methods: this cross-sectional study, conducted at the Hospital of Mental Health and Psychiatric Diseases in Oujda, sought to explore the intricate interplay between stress, coping mechanisms, and the incidence of relapse among individuals diagnosed with schizophrenia. Over six months, data were collected from three hundred schizophrenia patients, encompassing demographic, clinical, stress, and coping-related variables. Results: analysis of the findings unveiled compelling associations between stress intensity, coping efficacy, and relapse vulnerability. Notably, heightened stress intensity emerged as a significant predictor of relapse occurrence, surpassing the mere exposure to stressors. Furthermore, inadequate coping strategies were found to significantly elevate the risk of relapse, underscoring the pivotal role of adaptive coping skills in mitigating relapse susceptibility. In addition to these associations, the study revealed intriguing insights into the demographic and clinical characteristics of the patient population. Predominantly male and urban-dwelling, the patients exhibited varying levels of education and employment status. A substantial proportion reported a history of substance abuse and psychiatric family history, indicating potential predisposing factors for relapse vulnerability. These findings underscore the imperative of integrating stress management interventions and fostering adaptive coping mechanisms within schizophrenia treatment paradigms. Early identification and targeted interventions aimed at ameliorating stress reactivity and enhancing coping proficiency. Also, it held promise for the reduction of relapse rates and the increase of long-term outcomes for individuals grappling with schizophrenia. Conclusion: by elucidating the nuanced dynamics of stress and coping in relation to relapse, this study contributes valuable insights to the development of tailored interventions and therapeutic strategies in schizophrenia management.

Serotonin syndrome is an iatrogenic disorder induced by serotonergic drug. It is characterised by a symptomatic polymorphism that may create confusion with other clinical conditions, delaying diagnosis and putting the vital prognosis at risk. In light of a case report and a literature review, we here report the clinical case of a patient presenting with confusion, psychomotor agitation, hyperreflexia and spontaneous myoclonus following simultaneous use of paroxetine and amitriptyline. The diagnosis of serotonin syndrome was made after ruling out other possible diagnoses. The patient was admitted to the intensive care unit. This clinical case highlights the importance of thoroughly understanding the clinical manifestations of serotonin syndrome to ensure early and appropriate therapeutic management.

chronic haemodialysis patients are a vulnerable population significantly affected by the COVID-19 pandemic, which has had a severe impact on people with co-morbidities and immune system depression, which increases the risk of infection and of developing severe form of COVID-19. The purpose of this study is to assess the impact of the COVID-19 pandemic on the mental health and quality of life of chronic haemodialysis patients. we conducted a descriptive cross-sectional survey among 175 chronic hemodialysis patients using the Mini International Neuropsychiatric Interview Moroccan Arab Version 5.0.0 scale, the Perceived Stress Scale, and the Quality of Life Scale for Chronic Hemodialysis Patients (KDQOL-SFTM 1.3). one hundred and seventy-five (175) participants were recruited, of whom 76 patients had COVID-19. COVID-19 infection was significantly associated with age (p=0.018), psychiatric disorders (p=0.00), a history of suicide attempts (p=0.006) and high-stress levels (p=0.01). The quality of life of chronic haemodialysis patients was significantly impaired in patients with COVID-19 (p=0.00), especially in subjects who were elderly (p=0.034), lived alone (p=0.004), had a history of organic (p=0.04), psychiatric (p=0.00), or substance abuse issues (p=0.003), as well as in patients with a symptomatic form (p=0.001), complications (p=0.00), or hospitalisation secondary to COVID-19 (p=0.00), and those with severe stress (p=0.00). the mental health and quality of life of chronic haemodialysis patients were mainly negatively influenced during the COVID-19 pandemic.